08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Advanomics, Sunshine Biopharma deal

Sunshine purchased U.S. Patent No. 8,236,935 from Advanomics, which owns about 23% of Sunshine. The patent covers all rights related to Sunshine’s Adva-27a in the U.S. Sunshine is planning a Phase I trial of the...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Sunshine Biopharma cancer news

Sunshine said it will re-domicile in Canada from a Colorado incorporation. The company said it is reincorporating for acquisition opportunities and financing opportunities available to Canadian corporations. Sunshine's Adva-27a , a small molecule topoisomerase II...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Advanomics, Sunshine Biopharma, Laboratoires Garmen Inc. deal

Sunshine said its Advanomics parent company will acquire Garmen for an undisclosed amount. Garmen will manufacture 1 kg of Adva-27a , the lead compound of Advanomics and Sunshine, which will be used to complete the...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Sunshine Biopharma, Institut National des Sciences Appliquees de Lyon deal

Sunshine acquired from the French government research lab worldwide patents covering Sunshine's anti-cancer compound Adva-27a , including U.S. Patent No. 8,236,935. The patent covers Gem-difluorinated C-glycoside compounds derived from podophyllotoxin, their preparation and their applications....
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

Sunshine Biopharma preclinical data

In vitro, Adva-27a killed significantly more multidrug-resistant SCLC tumor cells than generic etoposide. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc. (OTCBB:SBFM), Montreal, Quebec   Product: Adva-27a   Business: Cancer  ...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Clinical News

Sunshine Biopharma preclinical data

In vitro, Adva-27a was 16 times more effective at killing multidrug resistant human breast cancer cells than etoposide. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc. (OTCBB:SBFM), Montreal, Quebec   Product:...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Company News

Sunshine Biopharma, Jewish General Hospital deal

The biotech and hospital partnered to conduct preclinical and Phase I testing of Sunshine's Adva-27a to treat cancer. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Details were not disclosed. Sunshine Biopharma Inc. (OTCBB:SBFM),...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Company News

Sunshine Biopharma, Binghamton University deal

The biotech and university signed a three-year deal to conduct preclinical and Phase I testing of Sunshine's Adva-27a to treat breast and prostate cancer. Sunshine will provide partial funding and will have exclusive rights to...